Impact of statins on ALI/ARDS: A meta-analysis

Pulm Pharmacol Ther. 2016 Aug:39:85-91. doi: 10.1016/j.pupt.2016.06.010. Epub 2016 Jun 29.

Abstract

Background: Statins may be beneficial in treating acute lung injury (ALI) or acute respiratory distress syndrome (ARDS), but their application remains controversial.

Objectives: This meta-analysis of published studies investigated their potential benefit in ALI/ARDS treatment.

Methods: PubMed, EMBASE, Google Scholar and Cochrane databases were searched and all randomized controlled trials (RCT) and cohort studies with head-to-head comparison between statin and standard care were included.

Results: Three RCTs and six cohort studies were included. Overall, statins treatment had no significant effect on mortality compared with placebo (RCTs: OR = 0.99, 95% CI = 0.72, 1.37; cohorts: OR = 0.99, 95% CI = 0.71, 1.37). In addition, ventilator-free days were comparable between the two groups (RCTs: SMD = 0.08, 95% CI = -0.03, 0.19; cohorts: SMD = 0.06, 95% CI = -0.17, 0.29). The one-way sensitivity analysis confirmed the stability of results.

Conclusion: The results did not show that statins had effects on mortality and ventilator-free days among ALI/ARDS patients. However, this meta-analysis is limited by the number of RCTs included.

Keywords: 5-Hydroxymethylfurfural (PubChem CID: 237332); ALI; ARDS; Glutaric acid (PubChem CID: 743); Statins; coenzyme A (PubChem CID: 87642).

Publication types

  • Meta-Analysis
  • Review

MeSH terms

  • Acute Lung Injury / drug therapy*
  • Acute Lung Injury / mortality
  • Acute Lung Injury / physiopathology
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Respiration, Artificial / statistics & numerical data
  • Respiratory Distress Syndrome / drug therapy*
  • Respiratory Distress Syndrome / mortality
  • Respiratory Distress Syndrome / physiopathology
  • Treatment Outcome

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors